FDA approves Insulet SmartAdjust technology/Omnipod 5 for type 2 diabetes

      Good news for people with type 2 diabetes! The U.S. Food and Drug Administration (FDA) has approved a new technology called Insulet SmartAdjust, which can help automate insulin delivery. This technology is now part of the Omnipod 5 system, a tubeless, wearable device that connects wirelessly to a continuous glucose monitor (CGM) to adjust insulin delivery automatically.

      The Omnipod 5 consists of a small, plastic "pod" that sticks to your body and delivers insulin based on glucose readings sent from the CGM. Although the system automatically manages most of your insulin needs, users still have to make adjustments for meals and exercise.

      This approval is based on results from the SECURE-T2D trial, which included 305 adults with type 2 diabetes. The trial found that using the Omnipod 5 significantly lowered participants' HbA1c levels from 8.2% to 7.4% in just 13 weeks. The results were the same whether or not users were also taking a GLP-1 receptor agonist medication.

      This new technology offers a simpler, more automated way for people with type 2 diabetes to manage their insulin, potentially making life a bit easier for those living with this chronic condition.